Revumenib in Combination with Intensive Induction and Consolidation for Newly Diagnosed Patients with NPM1-mutated or KMT2A-rearranged Acute Myeloid Leukemia: Preliminary Results from the Phase 1b ETCTN 10596 study

Poster Presentation | Dec 5, 2025

Author

Mims AS, et al.

Congress

American Society of Hematology Annual Meeting 2025

Orlando, Florida | Dec 6 – 9, 2025